Hingham Institution for Savings heads into its Q1 earnings release on April 30 with short interest still near its highest level of the year, the ORTEX short score firmly elevated, and a President/COO selling $2.5 million of stock just weeks ago.
Short sellers remain deeply embedded in HIFS. Short interest is at 20.2% of the free float — down from a recent peak above 21.3% in mid-March, but still very high for a regional bank. The week-on-week pace of covering actually accelerated: shorts pulled back about 4% over the past seven days as the stock edged lower. Days to cover run at 7.5, meaning the position cannot unwind quickly. The ORTEX short score is 74.4, a reading that has barely moved all month — it ranged from 74.4 to 75.2 over the past two weeks. That consistency signals a deliberate, dug-in short thesis rather than a momentum trade.
The borrow market adds a wrinkle. Cost to borrow climbed sharply, rising 38% over the week to 1.92% — the highest daily reading since April 20 and up from a recent low of 1.30% on April 24. That said, it remains modest in absolute terms. Availability has eased relative to the tightest moments of the past year: the 52-week high on utilization touched 100%, but the current lending pool is around 63% lent out, leaving meaningful room for new shorts to build positions if sentiment sours after earnings. The combination — elevated SI, rising borrow cost, but no extreme availability squeeze — suggests shorts are maintaining rather than panicking.
The insider tape leans bearish. President and COO Patrick Gaughen sold 9,044 shares at $277.62 on March 17, a $2.5 million disposal that is the largest insider transaction in the dataset. Director Jacqueline Youngworth has made four separate sells since October 2025, trimming small parcels across a range of prices between $288 and $313. The CFO also sold 1,000 shares at $318 in January. Against that, the 90-day net figure is a positive 10,594 shares — explained by Julio Hernando's reported filing of 66,327 shares, a position held rather than a fresh open-market purchase. Stripping that out, the core management activity reads as consistent, quiet distribution.
The most recent earnings print gave shorts a short-lived win. On April 17, Q1 2026 results showed adjusted EPS of $4.79, nearly double the $2.78 from a year earlier, yet the stock fell 3.8% the next day and extended losses to -5.3% over the following week. Revenue of $12.5 million came in well below the year-ago $17.6 million — a divergence between bottom-line recovery and top-line contraction that framed the negative reaction. Earlier reports told a different story: the Q4 2025 print on January 16 lifted the stock 1.3% on the day and 7.4% over the subsequent week. Two data points don't form a pattern, but the April reaction was noticeably weaker than January's despite a stronger headline EPS number. Institutional holders are concentrated: Royce & Associates added 11,251 shares in Q1 to reach 5.4% of shares outstanding, while DOMA Perpetual Capital built a 5.4% stake as of December.
The stock closed at $284.18 on April 29, down 2.3% on the day and essentially flat over the prior month after a brief recovery. Regional bank peers — ONB, EBC, and SBCF — all posted similar or slightly shallower weekly losses, suggesting the weakness is sector-wide rather than stock-specific. The RSI sits at a neutral 50, leaving the technical setup uninformative ahead of tonight's release. With shorts holding a 20%-plus free float position, cost to borrow ticking higher, and insiders who have been sellers at higher prices, the focus falls squarely on whether Q2 revenue guidance can close the gap between the EPS recovery story and the top-line contraction that spooked the market last time.
See the live data behind this article on ORTEX.
Open HIFS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
